a-synuclein

α-Synuclein (61-75) is a peptide fragment derived from the larger protein α-Synuclein. α-Synuclein is predominantly found in presynaptic nerve terminals and is considered to be a biomarker candidate for Parkinson's disease (PD).

Cuminaldehyde (Cuminal) 是一种具有抑制 α-突触核蛋白纤颤和细胞毒性作用的天然醛，是一种 Cuminum cyminum 的主要成分。它显示抗癌特性。

ELN484228 是一种 α-突触核蛋白的阻断剂。α-突触核蛋白是帕金森病中的关键蛋白质。

FMF-04-159-2是一种高效的共价型细胞周期蛋白依赖性激酶14（CDK14）抑制剂，对CDK14和CDK2的IC₅₀分别为39.6 nM和256 nM。FMF-04-159-2能够减少α-突触核蛋白（α-Syn）在神经元中的聚集并在帕金森病模型中发挥作用，也能够通过减弱Wnt β-catenin信号抑制三阴性乳腺癌（TNBC）的进展和转移。

Synucleozid is a potent the SNCA mRNA inhibitor that encodes α-synuclein protein (IC50=1.5 μM), has the potential for the investigation of Parkinson’s disease.

CBBR is an inhibitor of wild type and mutant alpha-synuclein aggregation. CBBR also a modulator of neurotoxicity.

α-Synucleinmodulator 1 (Compound 7k) 作为α-突触核蛋白（α-synuclein）的一种调节剂。其在ACN PBS（1:1）缓冲液中的最大吸收波长为386 nm，而最大发射波长则为603 nm。

OTs-PEG3-NHCO-Thalidomide 作为一种 PROTACα-synuclein degrader 6 的关键成分，既是泛素 E3 连接酶，也是连接子，主要应用于神经退行性疾病的研究领域。

L465046是一种用于治疗帕金森病的新型α-synuclein amyloid聚集抑制剂。

KAC-50.1 是 α-突触核蛋白的 PET 配体，其在重组 α-syn 纤维中针对位点 2 的 KD 值为 35 nM。

tau Protein α-synuclein-IN-2 (Compound 14T) 是一种可以穿透血脑屏障的tau和α-syn抑制剂。tau Protein α-synuclein-IN-2 通过硫脲连接子结构以剂量依赖方式减少α-syn的寡聚。该化合物在生物传感器细胞中阻止tau聚集的种子效应，并在M17D神经母细胞瘤模型中显示出抗包涵体效应。此外，tau Protein α-synuclein-IN-2 能够抑制Aβ斑块的形成，展示了其在阿尔茨海默病和帕金森病研究中的潜力。

Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) 是一种磷脂酰胆碱，能够延长 α-syn 聚集的滞后期，适用于帕金森病的研究。

Rasagiline-13C3is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo(ED50= 0.1 mg kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg kg) reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP) in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease. 1.Youdim, M.B.H., Gross, A., and Finberg, J.P.Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BBrit. J. Pharmacol.132(2)500-506(2001) 2.Youdim, M.B.H., and Weinstock, M.Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-YL)-ethyl methyl carbamate]Cell. Mol. Neurobiol.21(6)555-573(2001) 3.Kang, S.S., Ahn, E.H., Zhang, Z., et al.α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's diseaseEMBO J.37(12)e98878(2018)

DOPAL is an aldehyde product of the oxidative deamination of dopamine by monoamine oxidase.[1] It can be further oxidized to 3,4-dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase (ALDH) and, to a lesser extent reduced to 3,4-dihydroxyphenyl ethanol (DOPET). DOPAL is toxic to neurons.[2],[3] It can also oligomerize and precipitate α-synuclein, an event associated with Parkinson's disease.[2] Mice lacking cytosolic and mitochondrial forms of ALDH display increased levels of DOPAL as well as neurodegeneration and motor dysfunction characteristic of Parkinson’s disease.[4]

Corynoxine 是从大叶钩藤中分离出的一种四环羟吲哚生物碱。它是一种自噬增强剂，可通过Akt mTOR 途径促进 α-突触核蛋白的清除。

Acetylcorynoline (O-Acetylcorynoline) 是提取自 Corydalis bungeana 中的一种主要生物碱成分，具有抗炎活性。

α-Synuclein inhibitor 3 (Compound 7g) is a potent inhibitor of α-synuclein (α -Syn) aggregation. It has potential applications in Parkinson's disease research [1].

α-Synuclein inhibitor 4 (compound 3gh) is a highly effective and blood-brain barrier-permeable inhibitor of α-Synuclein aggregation. It displays potent activity, with an IC50 value of 0.98 μM, and exhibits a remarkable inhibition ratio of 91.2% at a concentration of 30 μM [1].

α-Synuclein inhibitor 6 (compound 3ge) is a highly effective and blood-brain barrier-permeable inhibitor that targets the aggregation of α-Synuclein (α-Syn). It exhibits a potent inhibitory activity, with an IC50 value of 1.70 μM, leading to a remarkable inhibition ratio of 94.4% at 30 μM [1].

Dyrk1A α-synuclein-IN-1 (Compound b1) 是一种双重的 Dyrk1A (IC50: 177 nM) 和 α-synuclein aggregation (IC50: 10.5 μM) 抑制剂。Dyrk1A α-synuclein-IN-1 表现出较好的预测 CNS 渗透性和神经保护活性。

α-Synuclein inhibitor 5 是一种有效的、能够透过血脑屏障的 α-Synuclein (α-Syn) 聚集的抑制剂 (IC50: 1.22 μM)，在 30 μM 时的抑制率为 94.3%。

Dyrk1A α-synuclein-IN-2 (Compound b20) 是一种双重的 Dyrk1A 和α-synuclein aggregation 的抑制剂，能够作用于α-synuclein (IC50: 7.8 μM)。Dyrk1A α-synuclein-IN-2 具有较高的预测 CNS 渗透性和神经保护作用。

20S Proteasome activator 1 是一种 20S 蛋白酶激活剂，对胰蛋白酶样位点、胰凝乳蛋白酶样位点和半胱天冬酶位点的 IC50 分别为 0.3 μM、0.7 μM 和 1.8 μM。20S Proteasome activator 1 通过在细胞系统中翻译来防止致病性 α-synuclein A53T 突变体积累从而减少疾病发生的概率。20S Proteasome activator 1 可用于研究神经退行性疾病。

CLR01 is a molecular tweezer. CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy. CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS. CLR01 inhibits Ebola and Zika virus infection. CLR01 Stabilizes a Disordered Protein-Protein Interface. CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.